MetaCap

AbCellera Biologics (ABCL) vs Amylyx Pharmaceuticals (AMLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 176.1% versus a gain of 77.4%. Amylyx Pharmaceuticals is the larger company by market cap ($3.35 billion vs $3.16 billion), about 1.1 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%AMLX+77.37%
+339%+150%-40%
Nov 21, 20251 yearNov 20, 2026
ABCL-18.02%AMLX+44.00%
+137%+18%-102%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus AMLX key metrics
MetricABCLAMLX
Share price$9.69$26.02
Market cap$3.16B$3.35B
1-day change-7.45%-0.69%
YTD return+183.33%+115.40%
1-year return+176.07%+77.37%
5-year return-30.74%—
EPS (TTM)$-0.48$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M$0
Revenue growth (YoY)+160.56%-100.00%
Net income (latest FY)$-146.41M$-144.74M
Operating margin-288.98%—
Net margin-194.88%—
52-week high$15.02$41.14
52-week low$2.75$10.83
Distance from 52-week high-35.46%-36.75%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+65.26%
Average volume4.34M1.53M
Shares outstanding326.62M128.56M
Employees562136
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed AMLX by 98.7 percentage points over the past year.
  • AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs -100.00%).

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

ABCL vs AMLX FAQ

Which is bigger, AbCellera Biologics or Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.35B compared with $3.16B for AbCellera Biologics (ABCL).

Which stock has performed better over the past year, ABCL or AMLX?

ABCL returned +176.07% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Amylyx Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons